EcoDrugPlus

Lysyl Oxidase-Like 2a

Ensembl ID : ENSORLG00000016809
Gene Symbol: LOXL2A
4 Cross references
209 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSORLG00000016197
Gene Symbol: LOXL2B
4 Cross references
210 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSORLG00000003850
Gene Symbol: MIF
4 Cross references
229 Possible Orthologues:

Macrophage Stimulating 1 Receptor B

Ensembl ID : ENSORLG00000014291
Gene Symbol: MST1RB
3 Cross references
193 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSORLG00000003505
Gene Symbol: LOC101175393
3 Cross references
188 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSORLG00000007318
Gene Symbol: MMP14A
4 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSORLG00000012159
Gene Symbol: MMP14B
3 Cross references
196 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSORLG00000013688
Gene Symbol: MMP2
3 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSORLG00000006340
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:

Matrix Metalloproteinase-20-Like

Ensembl ID : ENSORLG00000014508
Gene Symbol: LOC101156910
3 Cross references
163 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSORLG00000000484
Gene Symbol: MTOR
1 Cross references
215 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSORLG00000026268
Gene Symbol: MTOR
1 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).